Genetic Evaluation in a Cohort of 126 Dutch Pulmonary Arterial Hypertension Patients

Pulmonary arterial hypertension (PAH) is a severe, life-threatening disease, and in some cases is caused by genetic defects. This study sought to assess the diagnostic yield of genetic testing in a Dutch cohort of 126 PAH patients. Historically, genetic testing in the Netherlands consisted of the an...

Full description

Saved in:
Bibliographic Details
Published in:Genes 2020-10, Vol.11 (10), p.1191
Main Authors: van den Heuvel, Lieke M., Jansen, Samara M. A., Alsters, Suzanne I. M., Post, Marco C., van der Smagt, Jasper J., Handoko-De Man, Frances S., van Tintelen, J. Peter, Gille, Hans, Christiaans, Imke, Vonk Noordegraaf, Anton, Bogaard, HarmJan, Houweling, Arjan C.
Format: Article
Language:English
Subjects:
Bone morphogenetic protein receptor type II
Counseling
Family medical history
Genes
Genetic aspects
Genetic screening
Genetic testing
Growth factors
Hypertension
Lung diseases
Mutation
Next-generation sequencing
Pulmonary arteries
Pulmonary hypertension
Statistical analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pulmonary arterial hypertension (PAH) is a severe, life-threatening disease, and in some cases is caused by genetic defects. This study sought to assess the diagnostic yield of genetic testing in a Dutch cohort of 126 PAH patients. Historically, genetic testing in the Netherlands consisted of the analysis of BMPR2 and SMAD9. These genes were analyzed in 70 of the 126 patients. A (likely) pathogenic (LP/P) variant was detected in 22 (31%) of them. After the identification of additional PAH associated genes, a next generation sequencing (NGS) panel consisting of 19 genes was developed in 2018. Additional genetic testing was offered to the 48 BMPR2 and SMAD9 negative patients, out of which 28 opted for NGS analysis. In addition, this gene panel was analyzed in 56 newly identified idiopathic (IPAH) or pulmonary veno occlusive disease (PVOD) patients. In these 84 patients, NGS panel testing revealed LP/P variants in BMPR2 (N = 4), GDF2 (N = 2), EIF2AK4 (N = 1), and TBX4 (N = 3). Furthermore, 134 relatives of 32 probands with a LP/P variant were tested, yielding 41 carriers. NGS panel screening offered to IPAH/PVOD patients led to the identification of LP/P variants in GDF2, EIF2AK4, and TBX4 in six additional patients. The identification of LP/P variants in patients allows for screening of at-risk relatives, enabling the early identification of PAH.
ISSN:2073-4425
2073-4425
DOI:10.3390/genes11101191